Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CCR3 | P51677 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368748 | 0.84 | TP53 (0.48) | POLBKMT2AALDH1A1SIGMAR1 | |
| SCHEMBL5664554 | 0.83 | CCR3 (0.50) | POLBBCHEACHEKMT2AMEN1 | |
| SCHEMBL5664557 | 0.83 | CCR3 (0.50) | POLBBCHEACHEKMT2AMEN1 | |
| SCHEMBL28779126 | 0.80 | CCR3 (0.56) | POLBKMT2AMEN1CCR3HRH3 | |
| SCHEMBL14368758 | 0.76 | HPGD (0.43) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL28944413 | 0.76 | EPHX2 (0.56) | KMT2AMEN1CCR3SMN1; SMN2ALDH1A1 | |
| SCHEMBL14368746 | 0.76 | EPHX2 (0.56) | KMT2AMEN1CCR3SMN1; SMN2ALDH1A1 | |
| SCHEMBL28783269 | 0.75 | MCHR1 (0.52) | POLBCCR3HRH3SIGMAR1 | |
| SCHEMBL14368687 | 0.75 | EPHX2 (0.60) | POLBCCR3HRH3ALDH1A1SIGMAR1 | |
| SCHEMBL14368694 | 0.75 | MCHR1 (0.52) | POLBCCR3HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | POLB 4668/4885BCHE 2441/4885ACHE 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.